An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss
- Design
- Animal study · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Not human evidenceVERY_INDIRECT: lean and diet-induced obese mice; no human data.
- Could weight loss explain it?
- Not applicableNot applicable: the main outcomes are weight and fat loss with lean-mass preservation, which is body composition itself.
- Study tier
- Study tier 4VERY_LOW: a preclinical mouse study with no animal numbers or statistics in the abstract.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
In lean and diet-induced obese mice, an experimental RNA drug (Zfp423 ASO) that switches on fat-burning tissue was tested alone and with semaglutide. The combination produced more weight and fat loss than either drug alone while keeping lean mass. This is animal evidence only, and the abstract gives no numbers.
01Findings
What the study reported
- Drugs
- Semaglutide
- Comparator
- semaglutide alone and Zfp423 ASO alone (either monotherapy)
- Primary outcome
- weight and fat loss, lean-mass preservation and metabolic outcomes with semaglutide plus Zfp423 ASO versus either alone
- Effect
- Zfp423 ASO plus semaglutide gave greater weight and fat loss than either monotherapy while preserving lean mass and improving metabolic outcomes; no numbers reported
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Mouse-only study with no animal numbers or statistics in the abstract; the combination comparison mainly tests the add-on ASO, and two authors are employees of the company holding patents on ASO chemistry.
Who was studied
- Obesity status
- mixed (lean and diet-induced obese mice)
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- diet-induced obesity (mice)
Study quality details
- Study design
- Preclinical (animal)
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- semaglutide alone and Zfp423 ASO alone (either monotherapy)
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- VERY_INDIRECT
- Statistical precision
- no CI reported; group sizes not given
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- Two authors are Ionis Pharmaceuticals employees and one sits on the Novartis board; Northwestern University has filed a provisional patent on the Zfp423 ASOs, with two authors listed as inventors.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Current obesity therapies reduce weight but often fail to preserve lean mass or sustain metabolic benefit. Glucagon-like peptide-1 receptor agonists (GLP-1RA) improve obesity-associated metabolic disease, but weight loss is often accompanied by reduced energy expenditure, loss of lean mass, and rapid fat-predominant regain after treatment discontinuation. We hypothesized that pharmacologic activation of adipose thermogenesis could specifically target fat loss, complement appetite suppression by increasing energy expenditure, and improve the metabolic quality of weight loss. Guided by our finding that diet-induced thermogenesis is mediated by a zinc finger protein 423 (ZFP423)-controlled pathway, we developed adipose-directed antisense oligonucleotides (ASOs) targeting ZFP423, a transcriptional repressor of brown and beige adipocyte identity. In lean and diet-induced obese mice, weekly Zfp423 ASO treatment induced white adipose beiging, increased body temperature and oxygen consumption, and improved glucose homeostasis, insulin sensitivity, lipid metabolism, mitochondrial respiration, and hepatic steatosis. When combined with the GLP1-RA semaglutide, Zfp423 ASO produced greater weight and fat loss than either monotherapy while preserving lean mass and improving metabolic outcomes. These findings identify Zfp423 as an RNA therapeutic target and support adipose thermogenesis as a complementary strategy for metabolically healthier obesity treatment.